Exicure, Inc. (XCUR)
NASDAQ: XCUR · Real-Time Price · USD
2.400
-0.120 (-4.76%)
At close: Jun 26, 2026, 4:00 PM EDT
2.390
-0.010 (-0.42%)
After-hours: Jun 26, 2026, 7:48 PM EDT
Exicure Employees
Exicure had 2 employees as of March 31, 2026. The number of employees decreased by 6 or -75.00% since the number was last reported on December 31, 2025.
Employees
2
Change
-6
Growth
-75.00%
Revenue / Employee
n/a
Profits / Employee
-$4,892,000
Market Cap
15.30M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Quince Therapeutics | 38 |
| Lunai Bioworks | 29 |
| Citius Pharmaceuticals | 23 |
| Moleculin Biotech | 17 |
| Atossa Therapeutics | 16 |
| Werewolf Therapeutics | 14 |
| Tempest Therapeutics | 5 |
| GT Biopharma | 1 |
XCUR News
- 17 days ago - Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement - GlobeNewsWire
- 26 days ago - Exicure receives noncompliance notification from Nasdaq - TheFly
- 26 days ago - Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q - GlobeNewsWire
- 2 months ago - Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100) - GlobeNewsWire
- 3 months ago - Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions - GlobeNewsWire
- 3 months ago - Exicure, Inc. Reports Full Year 2025 Financial Results - GlobeNewsWire
- 5 months ago - Exicure announces publication of results from Phase 2 study of burixafor - TheFly
- 5 months ago - Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant - GlobeNewsWire